Molecular biopathology of thyroid tumors
|
|
- Philip Thompson
- 6 years ago
- Views:
Transcription
1 Molecular biopathology of thyroid tumors Philippe Vielh MD, PhD, FIAC Director of Cytopathology Deputy Director of Anatomic Pathology National Health Laboratory of Luxembourg Past President of the International Academy of Cytology Conflict of interest: no disclosure
2 OUTLINES Background Current evaluation of thyroid gland lesions Carcinogenesis model(s) Is it useful to assess genetic alterations on FNAC? Conclusions
3 BACKGROUND Thyroid nodules are frequent (2-30%) Carcinomas are rare (5%) and most are differentiated L. Da Vinci, 1500 Most differentiated carcinomas are of good prognosis Goya, 1804
4 Lazzeri D, et al. Thyroid (2015);25:
5 Lazzeri D, et al. Thyroid (2015);25:
6 Prevalence of thyroid nodules vs age Mazzaferri EL, N Engl J Med,1993,328:
7 DTC: Incidence and extent of disease Increasing incidence of cancers (3%-6%/year for 30 years). Attributed mainly to improved screening T3 T4: stable incidence ~10% Distant metastases:<10% of patients with clinical differentiated TC. Cancer is present in only 5% of all thyroid tumors: diagnosis is first based on FNAC Sassolas et al. Eur J Endocrinol 2009;160:71
8 Furuya-KanamoriL, et al. J ClinOncol(2016) 34
9 Thyroid-Cancer Incidence and Related Mortality in South Korea, Data on incidence are from the Cancer Incidence Database, Korean Central Cancer Registry; data on mortality are from the Cause of Death Database, Statistics Korea. All data are age-adjusted to the South Korean standard population. AhnHS, et al. N EnglJ Med (2014) 371;19:
10 Penetration of Thyroid-Cancer Screening ( ) and Incidence of Thyroid Cancer (2009) in the 16 Administrative Regions of South Korea. Data on thyroidcancer screening are from the Korean Community Health Survey Database, Korea Centers for Disease Control and Prevention; data on incidence are from the Cancer Incidence Database, Korean Central Cancer Registry. AhnHS, et al. N EnglJ Med (2014) 371;19:
11 CURRENT EVALUATION OF THYROID GLAND LESIONS Clinical examination Ultrasonography (+/- scintigraphy) Biochemical dosages (TSH, calcitonine) Fine-needle aspiration cytology (FNAC) Thyroid Lymph-node compartment of the neck Histopathological evaluation if needed
12
13 Lymph-node compartments of the neck Figure 2: Lymph-node compartments of the neck Level VI is also known as the central neck compartment and includes the prelaryngeal, pretracheal, and paratracheal lymph nodes. Reproduced from Cooper and colleagues, by permission of the American Thyroid Association. Lancet 2013; 381:
14 ATA recurrence risk stratification system Lancet 2013; 381:
15 CARCINOGENESIS MODELS Nikiforova M. Expert Rev. Mol. Diagn. 2008;8:83
16 Carcinogenesis models Kondo T. Nature Rev Cancer 2006;6:292
17 Early genetic events Kondo T. Nature Rev Cancer 2006;6:292
18 Gene mutations in thyroid tumors Xing M, Nat Rev Cancer 2013,13:
19 Model of multistep carcinogenesis Pallante, P. et al. Nat. Rev. Endocrinol. 2014,10; Figure 1 Classification of human thyroid carcinomas and subtype-specific genetic alterations. The thyroid gland contains follicular cells and C cells (also known as parafollicular cells). The vast majority of benign thyroid tumours are FTAs that often carry mutations in the RAS gene. MTCs derive from C cells and often have mutations in the proto-oncogene RET. RAS mutations and PAX8 PPARG translocation have been associated with FTCs. Follicular-cell-derived carcinomas can be subdivided into three categories: well-differentiated, poorly differentiated and undifferentiated thyroid carcinomas or ATCs. Well-differentiated thyroid carcinomas can be further classified under the PTC and FTC subtypes. Rearrangements lead to the formation of the RET/PTC oncogene, which is often found in PTC. Rearrangements involving NTRK1 together with point mutations in RAS and BRAF are also involved in the development of PTC. Deregulation of the PI3K AKT pathway through mutations affecting PIK3CA, PTEN, AKT1, CTNNB1, as well as loss of the tumour suppressor retinoblastoma (RB), is involved in the loss of differentiation, thereby leading from PTC and FTC to undifferentiated carcinomas. P53 mutations lead to a completely undifferentiated state in ATC. Abbreviations: ATC, anaplastic thyroid carcinomas; FTA, follicular thyroid adenomas; FTC, follicular thyroid carcinomas; MTC, medullary thyroid carcinoma; PTC, papillary thyroid carcinoma.
20 Bible KC, et al. Nat Rev Clin Oncol (2016);13:
21 Raue F, et al. Clin Cancer Res (2016);22(20):
22 Models of carcinogenesis Xing M, Nat Rev Cancer 2013,13: Figure 3 Model of the progression of thyroid tumorigenesis driven by the MAPK and PI3K AKT pathways. Activation of the MAPK pathway by genetic alterations, such as the BRAFV600E mutation, primarily drives the development of papillary thyroid cancer (PTC) from follicular thyroid cells. By contrast, activation of the PI3K AKT pathway by genetic alterations, such as mutations in RAS, PTEN and PIK3CA, primarily drives the development of follicular thyroid adenoma (FTA) and follicular thyroid cancer (FTC) from follicular thyroid cells. Conversion from FTA to FTC is largely due to increasing activation of the PI3K AKT pathway. As genetic alterations accumulate and intensify the signalling of each of the two pathways, PTC and FTC can progress to poorly differentiated thyroid cancer (PDTC). When both pathways are fully activated through accumulated genetic alterations, conversion from PDTC to anaplastic thyroid cancer (ATC) is strongly facilitated. It is also possible that PDTC and ATC can both develop de novo directly from follicular thyroid cells, and that ATC can develop from PTC or FTC if appropriate genetic alterations occur. Many secondary molecular alterations also progressively accumulate and synergize with the two pathways in driving the progression of thyroid tumorigenesis, as discussed in the text (not shown in the figure). The increasing number of vertical arrows and colour intensity of the ovals symbolize the increasing genetic alterations and signalling of the two pathways as thyroid tumorigenesis progresses. The figure is modified from REF. 33 (2007) American Association for Cancer Research.
23 Clinical management Pathologic differentiation Well-differentiated: follicular, papillary, medullary Others: poorly-differentiated, undifferentiated Tumour stage Early Others: advanced, metastatic, persistent, recurrent
24 Clinicopathological features in adults Xing M, Nature Rev Cancer 2013;184:199
25 Clinicopathological features in adult Kondo T. Nature Rev Cancer 2006;6:292
26 Clinicopathological features in childhood Yamashita S. Nature Clin Practice Endocrinol Met 2007;3:422
27 Treatment Primary surgery + adjuvant treatment for well-differentiated tumours at an early phase Targeted therapy for poorly or undifferentiated carcinomas as well as in - persistent, recurrent - advanced or metastatic tumours
28 Cell type and risk of cancer Santoro M. Nature Clin Practice Endocrinol Metabol 2006;2:42
29 Consequences of molecular lesions Santoro M. Nature Clin Practice Endocrinol Metabol 2006;2:42
30 IS IT USEFULNESS TO ASSESS GENETIC ALTERATIONS ON FNAC? At diagnosis? in well-differentiated tumours detected at an early stage: papillary; medullary; follicular As predictor to treatment? for targeted therapy: poorly-differentiated or undifferentiated carcinomas and advanced, metastatic, persistent or recurrent tumours
31 At diagnosis? Adults Children & adolescents Filetti S. Nature Clin Practice Endocrinol Met 2006;2:384 Dinauer C. Curr Opin Oncol 2008;20:59
32 Prevalence in adults Nikiforov Y. Modern Pathol 2008;21:S37
33
34
35 RET gene rearrangements in thyroid papillary carcinoma Nikiforova M. Expert Rev. Mol. Diagn. 2008;8:83
36 Prevalence of genetic alt. in children vs adult thyroid papillary ca. Yamashita S. Nature Clin Practice Endocrinol Met 2007;3:422
37 Adult vs children genetic alterations in thyroid papillary carcinoma Yamashita S. Nature Clin Practice Endocrinol Met 2007;3:422
38 Papillary carcinoma tumorigenesis Sobrinho-Simoes M. Virchows Arch 2005;447:787
39 Follicular variant of papillary carcinoma tumorigenesis Sobrinho-Simoes M. Virchows Arch 2005;447:787
40 Molecular pathways of various thyroid papillary carcinoma Nikiforova M. Expert Rev. Mol. Diagn. 2008;8:83
41
42
43
44
45
46
47
48
49 Follicular lesions tumorigenesis Sobrinho-Simoes M. Virchows Arch 2005;447:787
50 (PAX8-)PPARgamma rearrangement
51 Molecular pathways of various thyroid follicular tumours Nikiforova M. Expert Rev. Mol. Diagn. 2008;8:83
52 Diff. diagnosis of follicular lesions Diagn Cytopathol 2008;36:438
53 Dual goal of thyroid nodule evaluation Yip L ,26:8-13 1) Accurately exclude thyroid malignancy High negative predictive value (NPV) High sensitivity 2) Effectively optimize initial surgical management High positive predictive value (PPV) High specificity
54 Molecular tests on FNAC Hodak SP, Thyroid 2013, 23, VERACYTE Afirma Commercially available (Multi) gene expression classifier (GEC) proprietary «Rule out» test (high NPV) Identifying lesions highly likely to be benign (therefore obviating the need for diagnostic surgery) or suspicious (!) Alexander EK (NEJM 2012,367: ) with 265 cytologically indeterminate nodules Rate of histologic malignancy = 32% NPV = 93% (PPV = 47%) Sensitivity = 92% i.e. 8% (7/85) of cancers uncorrectly identified as benign lesions Specificity = 52% i.e. 48% of benign nodules uncorrectly identified as «suspicious» Percentage of cancers missed in: AUS/FLUS = 10% FN/SFN = 10% Suspicious for malignancy = 6% Cost-effectiveness study (3200US dollars): Li H (JCEM 2011,96:E1719-E1726) In indeterminate FNAC, the unreliable NPV of 89% in nodules with suspicious cytologic results and the overall high false positive rate prevents the use of this test to guide appropriate surgical treatment.
55 Molecular tests on FNAC Hodak SP, Thyroid 2013, 23, ASURAGEN mirinform thyroid panel Commercially available «rule in» method (high PPV) identifying lesions highly associated with malignant histology Including point mutations : BRAF (V600E and K601E) and (N-, K-, and H-RAS hotspots in codons 12, 13 and 61) and rearrangements (RET/PTC1 and 3 and PAX8/PPARg) One of the non overlapping mutations is identified in up to 75% of papillary carcinomas and 70% of follicular carcinomas Nikiforov YE (JCEM 2011,96: ) with 513 histologically correlated (rate of histologic malignancy = 24%) lesions. For indeterminate cytology: PPV = 89% (NPV = 89%) Sensitivity = 61% Specificity = 98% Percentage of cancers missed in: AUS/FLUS = 37% FN/SFN = 43% Suspicious for malignancy = 32% In indeterminate FNAC, the high PPV and high specificity of the panel accurately identify nodules with a high risk of cancer but negative panel testing results still have a 14% risk of cancer Cost-effectiveness study (2250 US dollars): Yip L (JCEM 2012,97:E )
56 Molecular tests on FNAC Yip L ,26:8-13
57 Molecular tests on FNAC (AUS/FLUS) to guide surgery Gomberawalla A, ,26:14-21 FIGURE 1. Proposed algorithm using molecular testing to guide decision-making in patients with fine-needle aspiration biopsies in the atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) category. NPV, negative predictive value; PPV, positive predictive value.
58 Molecular tests on FNAC (FN/SFN) to guide surgery Gomberawalla A, ,26:14-21 FIGURE 2. Proposed algorithm using molecular testing to guide decision-making in patients with fine-needle aspiration biopsies in the follicular neoplasm/suspicious for follicular neoplasm (FN/SFN) category. NPV, negative predictive value; PPV, positive predictive value.
59 Molecular tests on FNAC (SMC) to guide surgery Gomberawalla A, ,26:14-21 FIGURE 3. Proposed algorithm using molecular testing to guide decision-making in patients with fine-needle aspiration biopsies in the suspicious for malignant cells (SMCs) category. NPV, negative predictive value; PPV, positive predictive value.
60 Molecular tests on FNAC for management of thyroid nodules Xing M, Lancet 2013,381: Figure 3: Algorithm for management of thyroid nodules on the basis of FNAB and molecular marker tests Depending on the cytology categories, molecular tests with high sensitivity and NPV (eg, gene expression classifi er) or high specifi city and PPV (eg, BRAF mutation) are chosen. Extent of surgery should be decided on the basis of the combined assessment of clinical, imaging, cytological, and molecular marker data. FNAB=fi ne needle aspiration biopsy. AUS/FLUS=atypia of undetermined signifi cance/follicular lesion of undetermined signifi cance. FN/SFN=follicular neoplasm/suspicious for follicular neoplasm. PTC=papillary thyroid cancer. NPV=negative predictive value. PPV=positive predictive value. Tx=total/near total thyroidectomy. LND=lymph node dissection.
61 Molecular tests on FNAC Yip L, ,26:8-13 TARGETED NEXT GENERATION SEQUENCING PANEL (ThyroSeq) Nikiforova MN, JCEM 2013,98:E o Expansion of the gene hotspots screened o Increase the number of gene hotspots evaluable with a low quantity of DNA o Improvement of the sensitivity of mutant allele detection EXOME NEXT GENERATION SEQUENCING
62 As therapeutic predictor?
63 MAPK and other pathways in thyroid tumors Figure 1 The MAPK and related pathways in thyroid cancer. Shown in the middle of the figure is the classical MAPK pathway leading from an extracellular mitogenic stimulus that activates a receptor tyrosine kinase (RTK) in the cell membrane, to RAS, RAF (shown as BRAF-V600E), MEK and ERK. ERK is activated by phosphorylation (P) and enters the nucleus where it upregulates tumour-promoting genes and downregulates tumour suppressor genes and thyroid iodide-handling genes. On the left side of the figure is the nuclear factor-κb (NF-κB) pathway, in which extracellular stimuli activate the pathway by acting on receptors in the cell membrane, leading to activation of the inhibitor of κb (IκB) kinase (IKK), resulting in the phosphorylation of IκB. Phosphorylated IκB becomes dissociated from NF-κB, which is normally bound with IκB in a complex and sequestered in the cytoplasm. Phosphorylated IκB undergoes ubiquitylation and proteasomal degradation. Free NF-κB then enters the nucleus to promote the expression of tumour-promoting genes. Through an undefined mechanism that is independent of MEK signalling, BRAF-V600E promotes the phosphorylation of IκB and the release of NF-κB, thus activating the NF-κB pathway. Shown on the right side of the figure is the RASSF1 mammalian STE20-like protein kinase 1 (MST1) forkhead box O3 (FOXO3) pathway. Activated by extracellular pro-apoptotic stimuli through membrane receptors, RASSF1A activates MST1. Activated MST1 then phosphorylates FOXO3 on Ser207. The resulting phosphorylated FOXO3 becomes dissociated from proteins in the cytoplasm proteins undergo proteasomal degradation, and phosphorylated FOXO3 enters the nucleus to promote the expression of proapoptotic genes in the FOXO pathway. BRAF-V600E directly interacts with and inhibits MST1 and prevents its activation by RASSF1A, thereby suppressing the proapoptotic signalling of the FOXO3 pathway. The downward arrow for the FOXO activities shown in the nucleus indicates this negative effect of BRAF-V600E on proapoptotic genes, which are normally upregulated by the RASSF1A MST1 FOXO3 pathway. The triple independent coupling of BRAF-V600E to the pathways shown here represents a unique and powerful mechanism of thyroid tumorigenesis driven by BRAF-V600E. DAPK1, death-associated protein kinase 1; HIF1A, hypoxia-inducible factor 1α; MMP, matrix metalloproteinase; NIS, sodium iodide symporter; TGFB1, transforming growth factor β1; TIMP3, tissue inhibitor of metalloproteinases 3; TPO, thyroid peroxidase; TSHR, thyroid-stimulating hormone receptor; TSP1, thrombospondin 1; UPA, urokinase plasminogen activator; UPAR, urokinase plasminogen activator receptor; VEGFA, vascular endothelial growth factor A. Xing M, Nat Rev Cancer 2013,13:
64 MAPK and PI3K-mTOR pathways in thyroid tumors Xing M, Lancet 2013; 381: Figure 1: MAPK and PI3K-AKT-MTOR pathways genetic alterations and therapeutic targets in thyroid cancer Right side shows the MAPK pathway; left side shows the PI3K-AKT- MTOR pathway. The two classic signalling pathways are coupled to the receptor thyrosine kinase (RTK) at the cell membrane which transduces extracellular growth signals into intracellular signalling downstream of the two pathways. RAS can couple the signalling from RTK to both pathways. PTEN terminates the PI3K signalling. Genetic RTK amplifi cations are common. Common activating mutations in the MAPK pathway include RET-PTC rearrangement, RAS mutation, and BRAF mutation. Common genetic alterations in the PI3K pathway include RAS mutation, PTEN mutation or deletion, PIK3CA mutation or amplifi cation, and AKT1 mutation. The two pathways, driven by these genetic alterations, have a fundamental role in thyroid tumorigenesis. Amplifi cations of RTK genes are also common. *Denotes therapeutic targets in the two pathways that are currently being actively tested clinically.
65 Strategies for targeting RET tyrosine kinase receptor activation Nikiforova M. Expert Rev Anticancer Ther 2008;8:625
66 Small molecule inhibitors of RET in current clinical trials for MTC Schlumberger M. Nat Clin Pract Endocrin Met 2008;4:22
67 Therapeutic stratification in anaplastic carcinoma Immunohistochemical detection of: EGFr : 58% PDGFrbeta : 16% HER2 : 16%
68 Cell-cycle regulation Kondo T. Nature Rev Cancer 2006;6:292
69 Cell-cell and cell-matrix interactions Kondo T. Nature Rev Cancer 2006;6:292
70 Anti-Vasculo-Endothelial-Receptors Kerbel R. N Engl J Med 2008;358:2039
71 Multitargeted therapy Deshpande H. Curr Op Oncol 2008;20:19
72 Bible KC, et al. Nat Rev Clin Oncol(2016);13:403-16
73 Bible KC, et al. Nat Rev Clin Oncol(2016);13:403-16
74 Raue F, et al. Clin Cancer Res (2016);22(20):
75 The Cancer Genome Atlas Research Network, Cell (2014) 159,
76 The Cancer Genome Atlas Research Network, Cell (2014) 159,
77 CONCLUSIONS FNAC is currently the best approach for characterizing thyroid nodules; common language suggested by the Bethesda consensus meeting; still a morphological «grey zone» which may be the niche for molecular tests also helpful to identify prognostic biomarkers as well as targets for precision medicine.
78 Grazie!
79 Physiology Kondo T. Nature Rev Cancer 2006;6:292
80 Oncocytic tumours tumorigenesis Sobrinho-Simoes M. Virchows Arch 2005;447:787
ASC Companion Meeting at the 2017 USCAP: Ancillary Molecular Testing in "Indeterminate. Thyroid Nodules: How Far Have We Come?
ASC Companion Meeting at the 2017 USCAP: Ancillary Molecular Testing in "Indeterminate Thyroid Nodules: How Far Have We Come? William C. Faquin, MD, PhD, Massachusetts General Hospital, Boston, MA The
More informationClinical and Molecular Approach to Using Thyroid Needle Biopsy for Nodular Disease
Clinical and Molecular Approach to Using Thyroid Needle Biopsy for Nodular Disease Robert L. Ferris, MD, PhD Department of Otolaryngology/Head and Neck Surgery and Yuri E. Nikiforov, MD, PhD Division of
More informationAmerican Society of Cytopathology Companion Society Symposium Uses and Misuses of Ancillary Tests in Cytopathology
American Society of Cytopathology Companion Society Symposium Uses and Misuses of Ancillary Tests in Cytopathology Zubair W. Baloch. MD, PhD. Professor of Pathology, UPENN Medical Center Perelman School
More informationDr Catherine Woolnough, Hospital Scientist, Chemical Pathology, Royal Prince Alfred Hospital. NSW Health Pathology University of Sydney
Dr Catherine Woolnough, Hospital Scientist, Chemical Pathology, Royal Prince Alfred Hospital NSW Health Pathology University of Sydney Thyroid Cancer TC incidence rates in NSW Several subtypes - Papillary
More informationMarkers in Thyroid Nodule Evaluation. Yuri E. Nikiforov, MD, PhD Division of Molecular & Genomic Pathology University of Pittsburgh Medical Center
Markers in Thyroid Nodule Evaluation Yuri E. Nikiforov, MD, PhD Division of Molecular & Genomic Pathology University of Pittsburgh Medical Center Disclosures Quest Diagnostics (consultant) UPMC/CBLPath
More informationSection 2 Original Policy Date 2013 Last Review Status/Date September 1, 2014
Policy Number 2.04.82 Molecular Markers in Fine Needle Aspirates of the Thyroid Medical Policy Section 2 Original Policy Date 2013 Last Review Status/Date September 1, 2014 Disclaimer Our medical policies
More information2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines
2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines Angela M. Leung, MD, MSc, ECNU November 5, 2016 Outline Workup of nontoxic thyroid nodule(s) Ultrasound FNAB Management of FNAB results
More informationLet s Make Sense of Present & Predict Future. In Light of Past 1/12/2016
The New Diagnostic Paradigms in Thyroid Surgical Pathology and Affects on Reporting of Thyroid Fine Needle Aspiration Specimens Deliberations, Criticisms & Discussions Zubair W. Baloch, MD, PhD. Professor
More informationTHYROID CYTOLOGY THYROID CYTOLOGY FINE-NEEDLE-ASPIRATION ANCILLARY TESTS IN THYROID FNA
ANCILLARY TESTS IN THYROID FNA Prof. Fernando Schmitt Department of Pathology and Oncology, Medical Faculty of Porto University Head of Molecular Pathology Unit, IPATIMUP General-Secretary of the International
More informationMolecular Diagnostics in Thyroid Tumors
USCAP 2011 Endocrine Pathology Society Companion Meeting Molecular Diagnostics in Thyroid Tumors Yuri E. Nikiforov, M.D., Ph.D. Department of Pathology University of Pittsburgh Medical Center Outline Overview
More informationThe Bethesda Indeterminate Categories: An Update to Diagnosis and Molecular Testing
William C. Faquin, MD, PhD Professor of Pathology Harvard Medical School Director, Head and Neck Pathology Massachusetts Eye and Ear Massachusetts General Hospital The Bethesda Indeterminate Categories:
More informationMolecular Markers in Fine Needle Aspirates of the Thyroid
Molecular Markers in Fine Needle Aspirates of the Thyroid Policy Number: 2.04.78 Last Review: 3/2014 Origination: 3/2013 Next Review: 3/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationACCME/Disclosures. Questions to Myself? 4/11/2016
The New Diagnostic Paradigms in Thyroid Surgical Pathology and Affects on Reporting of Thyroid Fine-Needle Aspiration Specimens Deliberations, Criticisms & Discussions Zubair W. Baloch, MD, PhD. Professor
More informationDilemmas in Cytopathology and Histopathology
Dilemmas in Cytopathology and Histopathology Yuri E. Nikiforov, MD, PhD Division of Molecular & Genomic Pathology University of Pittsburgh Medical Center, USA Objectives Discuss new WHO classification
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Molecular Markers for Fine Needle Aspirates of Thyroid Nodules MP-065-MD-DE Medical Management Provider Notice Date: 10/15/2018;
More informationMolecular Markers in Fine Needle Aspirates of the Thyroid
Medical Policy Manual Genetic Testing, Policy No. 49 Molecular Markers in Fine Needle Aspirates of the Thyroid Next Review: April 2019 Last Review: June 2018 Effective: July 1, 2018 IMPORTANT REMINDER
More informationMedical Policy Manual. Topic: Molecular Markers in Fine Needle Aspirates of the Thyroid. Date of Origin: April 2013
Medical Policy Manual Topic: Molecular Markers in Fine Needle Aspirates of the Thyroid Date of Origin: April 2013 Section: Genetic Testing Last Reviewed Date: April 2014 Policy No: 49 Effective Date: July
More informationUltrasound-Guided Fine-Needle Aspiration of Thyroid Nodules: New events
Ultrasound-Guided Fine-Needle Aspiration of Thyroid Nodules: New events Sandrine Rorive, M.D., PhD. Erasme Hospital - Université Libre de Bruxelles (ULB) INTRODUCTION The assessment of thyroid nodules
More informationMolecular Testing for Indeterminate Thyroid Nodules. October 20, 2018
Molecular Testing for Indeterminate Thyroid Nodules October 20, 2018 Patient 1: Left 1.0 cm AP x 1.6 cm transverse x 2.1 cm in length Well defined Isoechoic heterogeneous No calcification Grade 3 Vascularity
More information3/27/2017. Disclosure of Relevant Financial Relationships. Each year over 550,000 thyroid FNAs are performed in the U.S.!!! THYROID FNA: THE GOOD NEWS
Disclosure of Relevant Financial Relationships William C. Faquin, MD, PhD Director, Head and Neck Pathology Massachusetts Eye and Ear Massachusetts General Hospital Professor of Pathology Harvard Medical
More informationHow to Handle Thyroid FNA
How to Handle Thyroid FNA Maoxin Wu, MD, PhD Chief of Cytopathology Director of Fine Needle Aspiration (FNA) and Core Biopsy Services Clinical Professor, Department of Pathology Joint appointment, Department
More informationAPPROCCIO DIAGNOSTICO-TERAPEUTICO TERAPEUTICO AL CARCINOMA DIFFERENZIATO DELLA TIROIDE Sabato 6 aprile 2013 Aula Magna Nuovo Arcispedale S.
dal 1846 APPROCCIO DIAGNOSTICO-TERAPEUTICO TERAPEUTICO AL CARCINOMA DIFFERENZIATO DELLA TIROIDE Sabato 6 aprile 2013 Aula Magna Nuovo Arcispedale S. Anna Ruolo dell analisi genetica Maria Chiara Zatelli
More informationHow to Use Molecular Genetic Studies in Endocrine Disease? (in the Management of Well- Differentiated Thyroid Cancer) No Conflicts to Declare
How to Use Molecular Genetic Studies in Endocrine Disease? (in the Management of Well- Differentiated Thyroid Cancer) No Conflicts to Declare Quan-Yang Duh Professor of Surgery University of California,
More informationBuilding On The Best A Review and Update on Bethesda Thyroid 2017
Building On The Best A Review and Update on Bethesda Thyroid 2017 Syed Z. Ali, MD, FRCPath, FIAC Professor of Pathology and Radiology The Johns Hopkins Hospital, Baltimore, Maryland USA TBSRTC Diagnostic
More informationMolecular markers in thyroid cancers
Review Article DOI: 10.18203/issn.2456-3994.IntJMolImmunoOncol20172639 Molecular markers in thyroid cancers Alpa Nimesh Patel, Siddharth Singh Department of Internal Medicine, Pramukhswami Medical College,
More informationRossella Elisei. Department of Endocrinology, University Hospital, Pisa, Italy
Rossella Elisei Department of Endocrinology, University Hospital, Pisa, Italy THYROID CANCER IS RARE TUMOR AND REPRESENTS ONLY 3.8% OF ALL HUMAN TUMORS All human cancer Thyroid cancer MOST FREQUENT CANCER
More informationSezione di Endocrinologia e Medicina Interna Direttore: Prof. Ettore degli Uberti Dipartimento di Scienze Mediche Università degli Studi di Ferrara
Sezione di Endocrinologia e Medicina Interna Direttore: Prof. Ettore degli Uberti Dipartimento di Scienze Mediche Università degli Studi di Ferrara Endocrinology Overview of genetic markers Molecular markers
More informationMedical Policy. Title: Genetic Testing- Molecular Markers in Fine Needle Aspirates (FNA) of the Thyroid
Medical Policy Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Molecular Markers in Fine Needle Aspirates of the Thyroid Page 1 of 25 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Molecular Markers in Fine Needle Aspirates
More informationThyroid Nodules. Family Medicine Refresher Course Geeta Lal MD, FACS April 2, No financial disclosures
Thyroid Nodules Family Medicine Refresher Course Geeta Lal MD, FACS April 2, 2014 No financial disclosures Objectives Review epidemiology Work up of Thyroid nodules Indications for FNAB Evolving role of
More informationThyroid Nodules. Dr. HAKIMI, SpAK Dr. MELDA DELIANA, SpAK Dr. SISKA MAYASARI LUBIS, SpA
Thyroid Nodules ENDOCRINOLOGY DIVISION ENDOCRINOLOGY DIVISION Dr. HAKIMI, SpAK Dr. MELDA DELIANA, SpAK Dr. SISKA MAYASARI LUBIS, SpA Anatomical Considerations The Thyroid Nodule Congenital anomalies Thyroglossal
More informationThe Bethesda System for Reporting Thyroid Cytopathology, Laila Khazai 11/4/17
The Bethesda System for Reporting Thyroid Cytopathology, 2017 Laila Khazai 11/4/17 In Summary No major changes for cytologists. The clinical team is faced with different risk of malignancies (ROM) associated
More informationEvaluation and Management of Thyroid Nodules. Nick Vernetti, MD, FACE Palm Medical Group Las Vegas, Nevada
Evaluation and Management of Thyroid Nodules Nick Vernetti, MD, FACE Palm Medical Group Las Vegas, Nevada Disclosure Consulting Amgen Speaking Amgen Objectives Understand the significance of incidental
More informationMaria Chiara Zatelli Sezione di Endocrinologia e Medicina Interna Direttore: Prof. Ettore degli Uberti Dipartimento di Scienze Mediche Università
Maria Chiara Zatelli Sezione di Endocrinologia e Medicina Interna Direttore: Prof. Ettore degli Uberti Dipartimento di Scienze Mediche Università degli Studi di Ferrara Molecular markers? Endocrinology
More informationPEDIATRIC Ariel Katz MD
PEDIATRIC Ariel Katz MD Dept. Otolaryngology Head &Neck Surgery Wolfson Medical Center Holon, Israel OBJECTIVES Overview/Background Epidemiology/Etiology Intro to Guidelines Workup Treatment Follow-Up
More informationCase year old female presented with asymmetric enlargement of the left lobe of the thyroid
Case 4 22 year old female presented with asymmetric enlargement of the left lobe of the thyroid gland. No information available relative to a prior fine needle aspiration biopsy. A left lobectomy was performed.
More informationCase 4 Diagnosis 2/21/2011 TGB
Case 4 22 year old female presented with asymmetric enlargement of the left lobe of the thyroid gland. No information available relative to a prior fine needle aspiration biopsy. A left lobectomy was performed.
More informationThyroid Update. Timothy C. Petersen, MD, ECNU
Thyroid Update Timothy C. Petersen, MD, ECNU TPMG Coastal Endocrinology Virginia Beach, VA About Me Board Certified Endocrinology, Diabetes, and Metabolism Internal Medicine ECNU Certified Endocrine Certification
More informationThyroid Nodule Management
Thyroid Nodule Management Shane O. LeBeau, MD Clinical Associate Professor of Medicine Clinical Lead, Endocrine Thyroid Unit Division of Endocrinology, Diabetes and Metabolism University of Pittsburgh
More informationThyroid Nodules: Understanding FNA Cytology (The Bethesda System for Reporting of Thyroid Cytopathology) Shamlal Mangray, MB, BS
Thyroid Nodules: Understanding FNA Cytology (The Bethesda System for Reporting of Thyroid Cytopathology) Shamlal Mangray, MB, BS Attending Pathologist Rhode Island Hospital, Providence, RI DISCLOSURE:
More informationMolecular Markers in Fine Needle Aspirates of the Thyroid Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory
2.04.78 Molecular Markers in Fine Needle Aspirates of the Thyroid Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory Effective Date November 26, 2014 Original Policy Date November 26, 2014 Next
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Molecular Markers in Fine Needle Aspirates of the Thyroid Page 1 of 40 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Molecular Markers in Fine Needle Aspirates
More informationWork Up & Evaluation of Thyroid Nodules In 2013: State of The Art
Work Up & Evaluation of Thyroid Nodules In 2013: State of The Art BC Surgical Oncology Network, Fall Update Todd McMullen MD PhD FRCSC FACS Endocrine Surgeon Divisions of General Surgery and Oncology Director,
More informationPersistent & Recurrent Differentiated Thyroid Cancer
Persistent & Recurrent Differentiated Thyroid Cancer Electron Kebebew University of California, San Francisco Department of Surgery Objectives Risk factors for persistent & recurrent disease Causes of
More informationTHYROID TUMOR DIAGNOSIS: MARKER OF THE MONTH CLUB
THYROID TUMOR DIAGNOSIS: MARKER OF THE MONTH CLUB CHARACTERISTIC OF THE IDEAL TUMOR MARKER Specific Sensitive Easy to perform Easy to interpret Adaptable to FNA Reasonable cost (CHEAP) THYROID TUMOR MARKERS
More informationMolecular Markers in Fine Needle Aspirates of the Thyroid
Molecular Markers in Fine Needle Aspirates of the Thyroid Policy Number: 2.04.78 Last Review: 9/2018 Origination: 3/2013 Next Review: 3/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationOncogenes/Growth Factors & Environment
Oncogenes/Growth Factors & Environment 8 th Postgraduate Course in Endocrine Surgery Crete, Greece September, 2006 Orlo H. Clark M.D. Thyroid Cancer Thyroid cancer is the 8 th most common and most rapidly
More information3/29/2012. Thyroid cancer- what s new. Thyroid Cancer. Thyroid cancer is now the most rapidly increasing cancer in women
Thyroid cancer- what s new Thyroid Cancer Changing epidemiology Molecular markers Lymph node dissection Technical advances rhtsh Genetic testing and prophylactic surgery Vandetanib What s new? Jessica
More informationVolume 2 Issue ISSN
Volume 2 Issue 3 2012 ISSN 2250-0359 Correlation of fine needle aspiration and final histopathology in thyroid disease: a series of 702 patients managed in an endocrine surgical unit *Chandrasekaran Maharajan
More informationRelated Policies None
Medical Policy MP 2.04.78 BCBSA Ref. Policy: 2.04.78 Last Review: 12/27/2017 Effective Date: 03/01/2018 Section: Medicine End Date: 09/27/2018 Related Policies None DISCLAIMER Our medical policies are
More information04/09/2018. Follicular Thyroid Tumors Updates in Classification & Practical Tips. Dissecting Indeterminants. In pursuit of the low grade malignancy
Follicular Thyroid Tumors Updates in Classification & Practical Tips Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology Chair of Pathology and Laboratory Medicine University
More informationMolecular Markers in Fine Needle Aspirates of the Thyroid
Molecular Markers in Fine Needle Aspirates of the Thyroid Policy Number: 2.04.78 Last Review: 3/2018 Origination: 3/2013 Next Review: 3/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationCalcitonin. 1
Calcitonin Medullary thyroid carcinoma (MTC) is characterized by a high concentration of serum calcitonin. Routine measurement of serum calcitonin concentration has been advocated for detection of MTC
More informationCase #1 FNA of nodule in left lobe of thyroid in 67 y.o. woman
Challenging Cases Manon Auger M.D., F.R.C.P. (C) Professor, Department of Pathology McGill University Director, Cytopathology Laboratory McGill University it Health Center Case #1 FNA of nodule in left
More informationMolecular Markers in Fine Needle Aspirates of the Thyroid
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationFine-needle aspiration (FNA) cytology plays an important
Update on Molecular Testing for Cytologically Indeterminate Thyroid Nodules Michiya Nishino, MD, PhD; Marina Nikiforova, MD Context. Approximately 15% to 30% of thyroid nodules that undergo fine-needle
More informationFollicular Derived Thyroid Tumors
Follicular Derived Thyroid Tumors Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology Chair of Pathology and Laboratory Medicine University of Arkansas for Medical Sciences
More information40 TH EUROPEAN CONGRESS 0F CYTOLOGY LIVERPOOL, UK October 2-5, 2016
Outcomes from the diagnostic approach of thyroid lesions using US-FNA and LBC in clinical practice Emmanouel Mastorakis MD PhD Cytopathologist Director in Cytopathology Laboratory Regional General Hospital
More informationNEOPLASMS OF THE THYROID PATHOLOGY OF PARATHYROID GLANDS. BY: Shifaa Qa qa
NEOPLASMS OF THE THYROID PATHOLOGY OF PARATHYROID GLANDS BY: Shifaa Qa qa Neoplasmas of the thyroid thyroid nodules Neoplastic ---- benign, malignant Non neoplastic Solitary nodules ----- neoplastic Nodules
More informationTBSRTC 1- Probabilistic approach and Relationship to Clinical Algorithms
The Benefits of a Uniform Reporting System for Thyroid Cytopathology BETHESDA REPORTING SYSTEM Prof. Fernando Schmitt Department of Pathology and Oncology, Medical Faculty of Porto University Head of Molecular
More informationMolecular testing of BRAF, RAS and TERT on thyroid FNAs with indeterminate cytology improves diagnostic accuracy
Accepted: 27 September 2017 DOI: 10.1111/cyt.12493 ORIGINAL ARTICLE Molecular testing of BRAF, RAS and TERT on thyroid FNAs with indeterminate cytology improves diagnostic accuracy M. Decaussin-Petrucci
More informationThyroid Nodules. No conflicts. Overview 5/16/2017. UCSF Internal Medicine Updates May 22, 2017 Elizabeth Murphy, MD, DPhil
Thyroid Nodules UCSF Internal Medicine Updates May 22, 2017 Elizabeth Murphy, MD, DPhil No conflicts Overview Thyroid nodule and cancer review Ultrasound FNA cytology Nodule follow up Putting it all together
More information5/3/2017. Ahn et al N Engl J Med 2014; 371
Alan Failor, M.D. Clinical Professor of Medicine Division of Metabolism, Endocrinology and Nutrition University of Washington April 20, 2017 No disclosures to report 1. Appropriately evaluate s in adult
More informationCN 925/15 History. Microscopic Findings
CN 925/15 History 78 year old female. FNA indeterminate lesion right thyroid lobe. Previous THY1C (UK) Bethesda category 1 cyst fluid. Ultrasound showed part solid/cystic changes, indeterminate in nature
More informationBackground to the Thyroid Nodule
William C. Faquin, MD, PhD Professor of Pathology Harvard Medical School Director of Head and Neck Pathology Massachusetts Eye and Ear Massachusetts General Hospital THYROID FNA: PART I Background to the
More informationPOORLY DIFFERENTIATED, HIGH GRADE AND ANAPLASTIC CARCINOMAS: WHAT IS EVERYONE TALKING ABOUT?
POORLY DIFFERENTIATED, HIGH GRADE AND ANAPLASTIC CARCINOMAS: WHAT IS EVERYONE TALKING ABOUT? AGGRESSIVE THYROID CANCERS PAPILLARY CARCINOMA CERTAIN SUBTYPES POORLY DIFFERENTIATED CARCINOMA HIGH GRADE DIFFERENTIATED
More informationUPDATE ON THE Bethesda system for reporting thyroid cytology
UPDATE ON THE Bethesda system for reporting thyroid cytology Esther Rossi MD PhD MIAC Division of Anatomic Pathology and Cytology Catholic University of Sacred Heart Rome, Italy Present < Current State
More informationMTP: Thyroid Nodules
Canadian Endocrine Update MTP: Thyroid Nodules Deric Morrison MD, FRCP, ECNU Assistant Professor, Division of Endocrinology and Metabolism, Western University April 2014 Faculty/Presenter Disclosure Faculty:
More informationImproving the Long Term Management of Benign Thyroid Nodules
25 th Annual Scientific AACE Clinical Congress Improving the Long Term Management of Benign Thyroid Nodules Stephanie L. Lee, MD, PhD Director, Thyroid Health Center Section of Endocrinology, Diabetes
More informationGerard M. Doherty, MD
Surgical Management of Differentiated Thyroid Cancer: Update on 2015 ATA Guidelines Gerard M. Doherty, MD Chair of Surgery Utley Professor of Surgery and Medicine Boston University Surgeon-in-Chief Boston
More informationPitfalls in thyroid tumor pathology. Prof.Valdi Pešutić-Pisac MD, PhD
Pitfalls in thyroid tumor pathology Prof.Valdi Pešutić-Pisac MD, PhD Too many or... Tumour herniation through a torn capsule simulating capsular invasion fibrous capsule with a sharp discontinuity, suggestive
More informationThyroid Neoplasm. ORL-Head and neck Surgery 2014
In The Name of God Thyroid Neoplasm ORL-Head and neck Surgery 2014 Malignant Neoplasm By age 90, virtually everyone has nodules Estimates of cancer prevalence at autopsy 4% to 36% Why these lesions are
More informationSurgical Management of Thyroid Disease. Tom Shi Connally, MD, FACS
Surgical Management of Thyroid Disease Tom Shi Connally, MD, FACS Disclosures Speaker Bureau: Veracyte Castle Diagnostics Objectives Understand the role of ultrasound and FNA in managing thyroid cancer
More informationDynamic Risk Stratification:
Dynamic Risk Stratification: Using Risk Estimates to Guide Initial Management R Michael Tuttle, MD Clinical Director, Endocrinology Service Memorial Sloan Kettering Cancer Center Professor of Medicine
More informationProtocol. Molecular Markers in Fine Needle Aspirates of the Thyroid
Protocol Molecular Markers in Fine Needle Aspirates of the Thyroid (20478) Medical Benefit Effective Date: 07/01/18 Next Review Date: 11/18 Preauthorization Yes Review Dates: 07/15, 07/16, 11/16, 11/17,
More informationMolecular Markers in Fine Needle Aspirates of the Thyroid
MEDICAL POLICY 12.04.510 Molecular Markers in Fine Needle Aspirates of the Thyroid BCBSA Ref. Policy: 2.04.78 Effective Date: Sept. 1, 2018 Last Revised: Aug. 14, 2018 Replaces: 12.04.78 and 2.04.78 RELATED
More informationCorrespondence should be addressed to David N. Bimston; Received 23 January 2017; Accepted 20 March 2017; Published 13 April 2017
Hindawi International Surgical Oncology Volume 2017, Article ID 4689465, 6 pages https://doi.org/10.1155/2017/4689465 Research Article Noninvasive Encapsulated Follicular Variant of Papillary Thyroid Cancer:
More informationINDEX. Note: Page numbers of issue and article titles are in boldface type. cell carcinoma. ENDOCRINE SURGERY
ENDOCRINE SURGERY INDEX Note: Page numbers of issue and article titles are in boldface type. Adenylate cyclase, in signal transduction 425-426 Adrenal incidentalomas, 499-509 imaging of, 502-504 in patients
More informationClinical Guidance in Thyroid Cancers. Stephen Robinson Imperial at St Mary s On behalf of BTA
Clinical Guidance in Thyroid Cancers Stephen Robinson Imperial at St Mary s On behalf of BTA Background to thyroid cancer Incidence probably increasing slowly 1971-95; 2.3 women 0.9 men /100,000 2001;
More informationUpdate on Thyroid FNA The Bethesda System. Shikha Bose M.D. Associate Professor Cedars Sinai Medical Center
Update on Thyroid FNA The Bethesda System Shikha Bose M.D. Associate Professor Cedars Sinai Medical Center Thyroid Nodules Frequent occurrence Palpable: 4-7% of adults Ultrasound: 10-31% Majority benign
More informationSurgery; 5 Biostatisctics Facility, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
THYROID Volume 25, Number 11, 2015 DOI: 10.1089/thy.2015.0305 Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular
More informationThyroid Cytopathology: Weighing In The Bethesda System
Thyroid Cytopathology: Weighing In The Bethesda System V8 Conflicts No financial consideration Bias Work in the Canadian environment where litigation is less Thyroid cytology is often referred in by small
More informationPromising New Treatments for Metastatic Differentiated and Medullary Thyroid Cancer. Marcia Brose MD PhD
Promising New Treatments for Metastatic Differentiated and Medullary Thyroid Cancer Marcia Brose MD PhD Department of Otorhinolaryngology: Head and Neck Surgery Department of Medicine, Division of Hematology/Oncology
More informationDifferentiated Thyroid Carcinoma
Differentiated Thyroid Carcinoma The GOOD cancer? Jennifer Sipos, MD Associate Professor of Medicine Director, Benign Thyroid Program Division of Endocrinology, Diabetes and Metabolism The Ohio State University
More informationThyroid nodules are common lesions encountered in the
Molecular Testing of Thyroid Nodules A Review of Current Available Tests for Fine-Needle Aspiration Specimens Ming Zhang, MD, PhD; Oscar Lin, MD, PhD Context. Fine-needle aspiration of thyroid nodules
More informationAACE-AME 2016 Thyroid Nodule Update
AACE-AME 2016 Thyroid Nodule Update 26 th Annual AACE Meeting & Clinical Congress Austin May 1-5, 2017 Hossein Gharib, MD, MACP, MACE Professor, Mayo Clinic College of Medicine Past President, American
More informationThyroid nodules - medical and surgical management. Endocrinology and Endocrine Surgery Manchester Royal Infirmary
Thyroid nodules - medical and surgical management JRE Davis NR Parrott Endocrinology and Endocrine Surgery Manchester Royal Infirmary Thyroid nodules - prevalence Thyroid nodules common, increase with
More informationNIFTP: Histopathology of a Cytological Monkey Wrench. B. Wehrli
NIFTP: Histopathology of a Cytological Monkey Wrench B. Wehrli Non-Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma Before 2016 Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like
More information4/22/2010. Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey.
Management of Differentiated Thyroid Cancer: Head Neck Surgeon Perspective Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey Thyroid gland Small endocrine gland:
More informationThyroid FNA: Diagnosis, Challenges and Solutions. Disclosures
Thyroid FNA: Diagnosis, Challenges and Solutions Zubair W. Baloch, MD, PhD None Disclosures 1 Questions to Myself? Where We are Now? The Present 2 Reality Check There is More to How Thyroid Nodules are
More informationPathology of the Thyroid
Pathology of the Thyroid Thyroid Carcinoma Arising from Follicular Cells 2015-01-19 Prof. Dr. med. Katharina Glatz Pathologie Carcinomas Arising from Follicular Cells Differentiated Carcinoma Papillary
More informationApproach to Thyroid Nodules
Approach to Thyroid Nodules Alice Y.Y. Cheng, MD, FRCPC Twitter: @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationPre-operative Ultrasound of Lymph Nodes in Thyroid Cancer
Pre-operative Ultrasound of Lymph Nodes in Thyroid Cancer AACE - Advances in Medical and Surgical Management of Thyroid Cancer - 2018 Robert A. Levine, MD, FACE, ECNU Thyroid Center of New Hampshire Geisel
More informationWhat s an NIFTP? Keeping Up To Date in Thyroid 2018
What s an NIFTP? Keeping Up To Date in Thyroid 2018 Kathleen Hands, MD, FACE, ECNU Director, Thyroid Center of South Texas Assistant Clinical Professor UTHSCSA DrHands@Thyroid-Center.com 210-844-6163 text
More informationHow good are we at finding nodules? Thyroid Nodules Thyroid Cancer Epidemiology Initial management Long-term follow up Disease-free status
New Perspectives in Thyroid Cancer Jennifer Sipos, MD Assistant Professor of Medicine Division of Endocrinology The Ohio State University Outline Thyroid Nodules Thyroid Cancer Epidemiology Initial management
More informationThe Frozen Section: Diagnostic Challenges and Pitfalls
The Frozen Section: Diagnostic Challenges and Pitfalls William C. Faquin, M.D., Ph.D. Director, Head and Neck Pathology Massachusetts General Hospital & Massachusetts Eye and Ear Infirmary Harvard Medical
More informationPediatric Thyroid Cancer Lung Metastases. Liora Lazar MD
Pediatric Thyroid Cancer Lung Metastases Liora Lazar MD Differentiated thyroid cancer (DTC) The 3rd most common solid tumor in childhood and adolescence Accounting for 1.5%-3% of all childhood cancers
More informationATA Guidelines for Medullary Thyroid Cancer: approach to initial management of sporadic and inherited disease
ATA Guidelines for Medullary Thyroid Cancer: approach to initial management of sporadic and inherited disease Richard T. Kloos, M.D. The Ohio State University Divisions of Endocrinology and Nuclear Medicine
More informationUtility of BRAF mutation detection in fine-needle aspiration biopsy samples read as suspicious for papillary thyroid carcinoma
ORIGINAL ARTICLE Utility of BRAF mutation detection in fine-needle aspiration biopsy samples read as suspicious for papillary thyroid carcinoma Sebastian M. Jara, MD, 1 Ramneesh Bhatnagar, MD, 2,4 Hui
More information